134 citations,
July 2020 in “Experimental dermatology” Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.
14 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” New therapies for alopecia areata show potential but need more research.
11 citations,
January 2020 in “Dermatologica Sinica” Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
6 citations,
February 2022 in “Journal of immunology research” Exosomes from fat-derived stem cells can potentially improve hair growth and could be a new treatment for immune-related hair loss.
4 citations,
April 2023 in “Autoimmunity reviews” High levels of IL6 and CRP, and low levels of vitamin D, might be indicators of alopecia areata.
4 citations,
March 2022 in “Dermatology and Therapy” People with moderate hair loss from Alopecia Areata feel more impacted than those with no or almost complete hair loss, and are more likely to seek treatment.
4 citations,
May 2019 in “Sultan Qaboos University Medical Journal” Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
3 citations,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
2 citations,
December 2022 in “Journal of the European Academy of Dermatology and Venereology” More people are seeing dermatologists for hair and scalp problems now than in the past.
2 citations,
October 2022 in “Current Dermatology Reports” People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.
1 citations,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
1 citations,
October 2022 in “International Journal of Molecular Sciences” Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.
1 citations,
September 2022 in “BioNanoScience” Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
September 2024 in “Journal of Cosmetic Dermatology” Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.
July 2024 in “Clinical Cosmetic and Investigational Dermatology” Non-drug therapies show promise for hair regrowth but need more research.
May 2024 in “Pigment International” Several treatments are effective for pigmentary disorders like vitiligo and melasma.
April 2024 in “Journal of translational medicine” MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
April 2024 in “Cosmetics” Wigs help improve self-esteem and quality of life for people with hair loss from alopecia areata.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
January 2024 in “Acta dermato-venereologica” November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
October 2023 in “The Cochrane library” The medicine baricitinib was found to notably improve hair regrowth in alopecia areata, but more research is needed on its side effects and other treatments.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
May 2023 in “Plastic and reconstructive surgery. Global open” Activated PRP injections are effective in treating hair loss and improving hair density.
January 2023 in “Dermatologic Therapy” Platelet-rich plasma therapy is a safe and effective treatment for alopecia areata.
January 2023 in “Annals of dermatology/Annals of Dermatology” A substance called miR-1246 may help treat severe hair loss by reducing certain immune cell activities.
ILC1-like cells can independently cause alopecia areata by affecting hair follicles.
55 citations,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.
19 citations,
July 2020 in “EBioMedicine” A gene variant increases the risk of a type of hair loss by affecting hair protein production.